Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?

Author： Mesplède Thibault   Wainberg Mark A.  

Publisher： MDPI

E-ISSN： 1999-4915|6|9|3377-3385

ISSN： 1999-4915

Source： Viruses, Vol.6, Iss.9, 2014-08, pp. : 3377-3385

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance mutations in the clinic. We believe that this is due to the long binding time of DTG to the integrase enzyme as well as greatly diminished replication capacity on the part of viruses that might become resistant to DTG. We further speculate that DTG might be able to be used in strategies aimed at HIV eradication.

Related content

High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia

By Tadesse Birkneh Tilahun   Kinloch Natalie N.   Baraki Bemuluyigza   Lapointe Hope R.   Cobarrubias Kyle D.   Brockman Mark A.   Brumme Chanson J.   Foster Byron A.   Jerene Degu   Makonnen Eyasu   Aklillu Eleni   Brumme Zabrina L.  

Viruses, Vol. 10, Iss. 2, 2018-02 ,pp. : 60-60 (1)

MDPI

Access to resources Recommend Favorite

Successful Treatment of Liver Aspergilloma by Caspofungin Acetate First-Line Therapy in a Non-Immunocompromised Patient

By Bai Qing-Xian   Huan Yi   Wang Jian-Hong   Yang Li-Jie   Dong Hong-Juan  

International Journal of Molecular Sciences, Vol. 13, Iss. 9, 2012-09 ,pp. : 11063-11070 (8)

MDPI

Access to resources Recommend Favorite

Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action

By Amaral Leonard   Viveiros Miguel  

Antibiotics, Vol. 6, Iss. 1, 2017-01 ,pp. : 3-3 (1)

MDPI

Access to resources Recommend Favorite

Drug Resistance in Cancer: An Overview

By Housman Genevieve   Byler Shannon   Heerboth Sarah   Lapinska Karolina   Longacre Mckenna   Snyder Nicole   Sarkar Sibaji  

Cancers, Vol. 6, Iss. 3, 2014-09 ,pp. : 1769-1792 (24)

MDPI

Access to resources Recommend Favorite

Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment

By Muinelo-Romay Laura   Vieito Maria   Abalo Alicia   Alonso Nocelo Marta   Barón Francisco   Anido Urbano   Brozos Elena   Vázquez Francisca   Aguín Santiago   Abal Miguel   López López Rafael  

Cancers, Vol. 6, Iss. 1, 2014-01 ,pp. : 153-165 (13)

MDPI

Access to resources Recommend Favorite